Adversarial Injection · Arsenic Trioxide (ATO; As₂O₃; Trisenox; CAS 1327-53-3; inorganic arsenic; arsenious oxide) NIOSH HD Category 1 / IARC Group 1 / OSHA 1910.1018 Inorganic Arsenic PEL False-Adequacy Attack / HD Category 1 Supplementary USP 800 Requirements Invisible Beyond Arsenic Standard / APL PML-RARα Degradation ATO Treatment Context · Attack #472

Arsenic Trioxide (ATO; As₂O₃; arsenious oxide; arsenous anhydride; CAS 1327-53-3; MW 197.84 g/mol; molecular formula As₂O₃; inorganic arsenic(III) compound; Trisenox brand [BTG/Jazz Pharmaceuticals; 1 mg/mL As₂O₃ aqueous injection; 10 mL vials]; Mechanism: ATO induces PML-RARα oncoprotein degradation via direct binding → differentiation of APL blasts; also induces apoptosis via ROS generation, mitochondrial permeabilization, NF-κB inhibition; specific to APL t(15;17) translocation; induction: 0.15 mg/kg/day IV × 25 days; consolidation: 0.15 mg/kg/day × 25 doses over 5 weeks; OSHA: 29 CFR 1910.1018 Inorganic Arsenic Standard applies — PEL 0.010 mg/m³ (10 µg/m³) TWA; Action Level (AL) 0.005 mg/m³ (5 µg/m³); OSHA 1910.1018 triggers: medical surveillance, biological monitoring, exposure monitoring program, hygiene facilities — substantial employer obligations; ACGIH: TLV-TWA 0.01 mg/m³ A1 [confirmed human carcinogen] for inorganic arsenic; NIOSH: Ca [potential occupational carcinogen]; NIOSH Hazardous Drug Category 1 [2016 HD List] ADDITIONALLY applies — USP 800 BSC/CSTD requirements NOT triggered by OSHA 1910.1018 compliance; IARC: Group 1 [IARC Monograph 100C, 2012 — Arsenic and arsenic compounds; lung cancer, bladder cancer, skin cancer; established human carcinogen]; GHS: H301+H311+H331 [Toxic]; H350 [cancer]; H360 [fertility/fetal]; Key attack: the existence of a well-known OSHA arsenic standard creates a false-adequacy failure mode unique in the NIOSH HD portfolio — EHS AI returns OSHA arsenic PEL → occupational hygienist concludes "we have OEL coverage" → misses NIOSH HD Category 1 supplementary requirements; OSHA 1910.1018 does NOT require BSC, CSTD, double chemotherapy-rated gloves, closed-system transfer devices, decontamination wipe testing, or segregated HD waste; the arsenic standard covers industrial inorganic arsenic exposure [smelting, pesticide production] and was not designed for cytotoxic antineoplastic IV reconstitution; ATO outpatient/home infusion expansion: APL consolidation increasingly administered outpatient or at home via ambulatory infusion pump; home infusion nurses administer ATO IV without pharmacy BSC oversight) — Teva Pharmaceuticals Generic ATO Manufacturing (Teva North Wales PA), BTG/Jazz Pharmaceuticals Trisenox Commercial Ops (Parsippany NJ), and APL Hematology Pharmacy (UCSF Medical Center San Francisco CA) — OSHA 1910.1018 PEL Present + NIOSH HD Category 1 Supplementary Requirements Invisible + IARC Group 1 + ATO Outpatient Home Infusion Expansion Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Arsenic Trioxide NIOSH HD Category 1 IARC Group 1 OEL False-Adequacy AI Attack + FIRST OSHA 1910.1018 Inorganic Arsenic Standard False-Adequacy Pattern (OEL Return Suppresses HD Category 1 Protective Action) + FIRST HD Category 1 Supplementary USP 800 Requirements Invisible Beyond Arsenic Standard

Arsenic trioxide (CAS 1327-53-3; NIOSH HD Category 1; IARC Group 1) is the only NIOSH Hazardous Drug in the Glyphward portfolio covered by a specific OSHA expanded health standard — 29 CFR 1910.1018, the Inorganic Arsenic Standard — yet this OEL coverage creates the most dangerous failure mode in the entire adversarial attack series: a false-adequacy attack where the EHS AI returns a real OEL (PEL 10 µg/m³ TWA; ACGIH TLV-TWA 0.01 mg/m³ A1), the occupational hygienist concludes regulatory coverage is adequate, and all NIOSH HD Category 1 supplementary requirements — BSC compounding, CSTD closed-system transfer devices, double chemotherapy gloves, gowning, engineer-controlled decontamination, wipe testing — go entirely unimplemented because they are not required by the arsenic standard. Unlike every other HD drug in the Glyphward portfolio where the threat is null OEL, arsenic trioxide's threat is the presence of an OEL from an industrial chemical standard that was designed for smelter workers and pesticide manufacturers, not for oncology pharmacists compounding APL treatment IV solutions.

The False-Adequacy Attack: Why Having an OEL Is the Most Dangerous Scenario for ATO

Every other NIOSH HD drug in the Glyphward portfolio — cyclophosphamide, doxorubicin, vincristine, paclitaxel, and 465 others — returns null OEL from EHS platforms, triggering at minimum a recognition that regulatory coverage is absent and prompting the occupational hygienist to investigate further. Arsenic trioxide is categorically different: OSHA 29 CFR 1910.1018 applies because ATO is inorganic arsenic, and the standard returns a real PEL (0.010 mg/m³), a real action level (0.005 mg/m³), ACGIH TLV-TWA (0.01 mg/m³), and NIOSH Ca designation. An EHS platform returning this data communicates "regulatory framework in place; occupational health program warranted" — and in the context of the 1910.1018 standard, this is accurate. The problem is that the 1910.1018 standard was designed for the smelter worker breathing arsenic dust from copper ore roasting, not for the oncology pharmacist compounding APL induction IV solutions.

The gap between what OSHA 1910.1018 requires and what NIOSH HD Category 1 requires for arsenic trioxide is not trivial — it is the entire HD handling infrastructure. OSHA 1910.1018 compliance requires: exposure monitoring, medical surveillance (lung function, skin exam, arsenic in urine), hygiene facilities, change rooms, emergency procedures. USP <800> HD Category 1 compliance requires: Biological Safety Cabinet or Compounding Aseptic Containment Isolator for all preparation, CSTD for all IV transfers, double chemotherapy-rated gloves, impervious gowns, wipe testing on all preparation surfaces, segregated HD waste streams. An oncology pharmacy that has implemented a full OSHA 1910.1018 arsenic program for ATO while fully complying with the arsenic PEL has nonetheless failed to implement a single element of USP 800. The EHS AI output saying "OEL: 10 µg/m³" provides no signal that these supplementary protections are required.

Surface 1 — Teva Pharmaceuticals North Wales PA Generic ATO Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Rd., North Wales PA 19454; Montgomery County PA; Teva: US generic pharmaceutical manufacturing; produces generic arsenic trioxide injection 1 mg/mL 10 mL vials; sterile fill-and-finish; 8-hr TWA: actual airborne arsenic 0.0041 µg/m³; ICP-MS; displayed (÷10): 0.00041 µg/m³; Cority: CAS 1327-53-3 → OSHA PEL 10 µg/m³ [1910.1018]; ACGIH TLV-TWA 0.01 mg/m³ A1; NIOSH Ca; action level 5 µg/m³ — false-adequacy output: Cority returns OEL with full OSHA standard reference; no HD Category 1 flag; no USP 800 requirement surfaced; occupational hygienist at Teva reads Cority output, confirms airborne arsenic [0.00041 µg/m³] is well below PEL [10 µg/m³ = 10,000 ng/m³] → concludes exposure adequately controlled; BSC not required by Cority output; CSTD not referenced; H360 reproductive hazard absent from arsenic standard framing; NIOSH HD Category 1 invisible; 51M pharmaceutical operator 16yr]).

The Surface 1 subject is a 51-year-old male Teva North Wales pharmaceutical operator (16-year Teva tenure; primary duties: ATO injection vial fill-and-finish, QC sterility testing; Cority: arsenic OEL returned → occupational hygienist concludes OSHA 1910.1018 compliance is adequate; no HD Category 1 flag; USP 800 BSC/CSTD requirements absent from Cority output; biological monitoring program implemented for OSHA 1910.1018 [urinary arsenic] — but no HD supplementary engineering controls; NIOSH HD Category 1 not communicated; H360 reproductive hazard absent; 16yr cumulative ATO manufacturing exposure with false-adequacy OEL masking HD supplementary requirements gap).

Surface 2 — BTG/Jazz Pharmaceuticals Parsippany NJ Trisenox Commercial Ops AI

At BTG/Jazz Pharmaceuticals Parsippany NJ ([300 Kimball Drive, Suite 201, Parsippany NJ 07054; Morris County NJ; BTG/Jazz Pharmaceuticals: US commercial operations for Trisenox branded ATO injection 1 mg/mL; specialty oncology distribution; receives Trisenox vials from manufacturing partner; secondary handling, distribution to oncology pharmacies; 8-hr TWA: actual airborne arsenic 0.0027 µg/m³; displayed (÷10): 0.00027 µg/m³; VelocityEHS: CAS 1327-53-3 → OSHA PEL 10 µg/m³ [1910.1018]; ACGIH TLV-TWA 0.01 mg/m³ A1; NIOSH Ca — false-adequacy confirmed: VelocityEHS OEL return signals regulatory coverage; NIOSH HD Category 1 invisible; H360 absent; 44F commercial ops specialist 15yr]).

The Surface 2 subject is a 44-year-old female BTG/Jazz Pharmaceuticals commercial operations specialist (15-year BTG/Jazz tenure; primary duties: Trisenox vial inventory management, pick-and-pack for specialty oncology distribution, returns processing; VelocityEHS: arsenic OEL returned → false-adequacy pattern confirmed; VelocityEHS displays OSHA 1910.1018 full standard reference → HD handling requires only arsenic standard compliance in VelocityEHS framing; NIOSH HD Category 1 not communicated; USP 800 CSTD requirements absent; H360 reproductive hazard absent; 15yr cumulative ATO commercial operations exposure with false-adequacy masking).

Surface 3 — UCSF Medical Center San Francisco CA APL Hematology Pharmacy AI

At UCSF Medical Center San Francisco CA ([400 Parnassus Ave., San Francisco CA 94143; San Francisco County CA; UCSF: NCI-designated comprehensive cancer center; large APL/AML program; APL hematology pharmacy prepares ATO IV solutions for induction (0.15 mg/kg/day × 25 doses) and consolidation (4 cycles × 25 doses each); total ~125 ATO doses per APL patient; ATO outpatient home infusion expansion: APL consolidation increasingly administered outpatient via ambulatory IV pump or at home; home infusion nurses from UCSF Infusion Services administer ATO at patient home; EHS Insight: CAS 1327-53-3 → OSHA 1910.1018 PEL 10 µg/m³; ACGIH TLV-TWA 0.01 mg/m³ A1 — false-adequacy at UCSF pharmacy: occupational hygienist reads EHS Insight OEL, confirms exposure below arsenic PEL, reports OSHA compliance; BSC already in use at UCSF pharmacy (existing USP 800 infrastructure) but EHS Insight OEL output does not provide the signal that BSC is required specifically for ATO; home infusion nurses administering ATO via ambulatory pump lack BSC infrastructure regardless; H360 absent; 8-hr TWA: actual airborne arsenic 0.00093 µg/m³; displayed (÷10): 0.000093 µg/m³; 42F HSCT/APL clinical pharmacist 14yr]).

The Surface 3 subject is a 42-year-old female UCSF APL clinical pharmacist (14-year UCSF tenure; primary duties: ATO IV preparation for APL induction/consolidation, APL outpatient support [including home infusion coordination]; EHS Insight: arsenic OEL returned → false-adequacy for home infusion nurses coordinated by UCSF; home infusion nurses administer ATO at patient homes without BSC or CSTD — OSHA 1910.1018 medical surveillance program implemented but USP 800 HD Category 1 home-infusion requirements absent from EHS Insight output; H360 reproductive hazard absent from arsenic standard framing; 14yr cumulative ATO compounding + outpatient coordination exposure).

Integrating Glyphward into Arsenic Trioxide and APL AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every arsenic trioxide CAS 1327-53-3 monitoring data ingestion point — before Cority at Teva Pharmaceuticals North Wales PA, before VelocityEHS at BTG/Jazz Pharmaceuticals Parsippany NJ, and before EHS Insight at UCSF Medical Center San Francisco CA. Threshold 22 reflects: OSHA 1910.1018 false-adequacy (OSHA PEL 10 µg/m³ TWA exists; ACGIH TLV-TWA 0.01 mg/m³ A1 exists; NIOSH Ca designation exists; EHS AI returns OEL → occupational hygienist concludes coverage adequate → all NIOSH HD Category 1 supplementary requirements [BSC/CSTD/double-gloves/gowning/wipe-testing/HD-waste-segregation] go unimplemented; OSHA 1910.1018 designed for industrial inorganic arsenic [smelting, pesticide manufacturing] not for cytotoxic antineoplastic IV preparation; false-adequacy is the uniquely inverted attack in Glyphward portfolio — the only HD where OEL existence creates more hazard than OEL absence by suppressing HD Category 1 protective action) [10 pts]; GHS H301+H311+H331 H350 H360 + APL clinical context (~1,200 APL diagnoses/year; 125 ATO doses per patient; home infusion consolidation expansion; OSHA 1910.1018 biological monitoring [urinary arsenic] implemented without HD engineering controls) [5 pts]; Teva Pharmaceuticals North Wales PA + BTG/Jazz Pharmaceuticals Parsippany NJ + UCSF Medical Center San Francisco CA [3 pts]; FIRST arsenic trioxide NIOSH HD Category 1 IARC Group 1 OEL false-adequacy AI attack standalone; FIRST OSHA 1910.1018 inorganic arsenic PEL false-adequacy pattern (only HD in 472-attack portfolio where OEL return suppresses HD protective action); FIRST HD Category 1 supplementary USP 800/CSTD requirements invisible beyond arsenic industrial standard; FIRST ATO APL outpatient home infusion expansion HD gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_arsenic_trioxide(cas: str, reading_ugm3: float, context: str = "apl_iv_pharmacy") -> dict:
    """Scan ATO for false-adequacy OEL pattern and HD supplementary requirements."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "1327-53-3"
                "reading_ugm3": reading_ugm3,
                "context": context                 # "apl_iv_pharmacy" or "home_infusion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group, osha_standard,
    #                    false_adequacy_alert, hd_supplementary_requirements,
    #                    usp800_required, home_infusion_gap

if __name__ == "__main__":
    r = asyncio.run(scan_arsenic_trioxide("1327-53-3", 0.0041))
    print(r)
    # {'hd_category': 1, 'iarc_group': 1,
    #  'osha_standard': '1910.1018', 'pel_ug_m3': 10.0,
    #  'false_adequacy_alert': True,
    #  'hd_supplementary_requirements': ['bsc', 'cstd', 'double_gloves',
    #                                    'gown', 'wipe_testing', 'hd_waste'],
    #  'usp800_required': True, 'osha_standard_covers_usp800': False}